Cadila Gets FDA Nod for Arthritis Drug (India)
This article was originally published in PharmAsia News
Executive Summary
Major Indian pharmaceutical manufacturer Zydus Cadila Healthcare announced on Sept. 25 that it has received approval from the U.S. FDA for a new drug to treat rheumatoid arthritis. The FDA approval is for a 200mg dose of hydrochloroquine sulfate. The drug is one of a class of arthritis-fighting treatments known as disease modifying anti-rheumatic drugs (DMARD). DMARDs are designed to reduce the pain, inflammation, and joint damage caused by the disease for a period of several weeks or several months depending on the treatment. (Click here for more
You may also be interested in...
FDA’s New Dataset Aims To Assist Labs In Assessing Medical Device Biocompatibility
The US FDA’s device center has unveiled a new public dataset designed to assist chemistry laboratories in ensuring the robustness of chemical characterization methods used to assess the biocompatibility of medical devices.
Sanofi Prepares Pulmonologists As Dupixent Nears COPD Finishing Line
The French drugmaker has identified education as a key challenge ahead of its June action date for the huge-selling IL4/IL-13 inhibitor in the lung condition. An approval would make it the first biologic for the disease.
Global Pharma Guidance Tracker – March 2024
Stay up to date on regulatory guidelines from around the world with the Pink Sheet's Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.